Identification of acylthiourea derivatives as potent Plk1 PBD inhibitors

Eur J Med Chem. 2016 Nov 29:124:229-236. doi: 10.1016/j.ejmech.2016.08.043. Epub 2016 Aug 22.

Abstract

Thiourea derivatives have drawn much attention for their latent capacities of biological activities. In this study, we designed acylthiourea compounds as polo-like kinase 1 (Plk1) polo-box domain (PBD) inhibitors. A series of acylthiourea derivatives without pan assay interference structure (PAINS) were synthesized. Four compounds with halogen substituents exhibited binding affinities to Plk1 PBD in low micromole range. The most potent compound (3v) showed selectivity over other subtypes of Plk PBDs and inhibited the kinase activity of full-length Plk1.

Keywords: Binding affinity; Halogenosulfamoylphenyl acylthiourea; In vitro assay; Polo-box domain; Polo-like kinase 1; Small molecular inhibitor.

MeSH terms

  • Cell Cycle Proteins / antagonists & inhibitors*
  • Cell Cycle Proteins / chemistry*
  • Cell Cycle Proteins / metabolism
  • Cell Proliferation / drug effects
  • Drug Evaluation, Preclinical
  • Halogens / chemistry
  • HeLa Cells
  • Humans
  • Molecular Docking Simulation
  • Polo-Like Kinase 1
  • Protein Domains
  • Protein Kinase Inhibitors / chemistry*
  • Protein Kinase Inhibitors / metabolism
  • Protein Kinase Inhibitors / pharmacology*
  • Protein Serine-Threonine Kinases / antagonists & inhibitors*
  • Protein Serine-Threonine Kinases / chemistry*
  • Protein Serine-Threonine Kinases / metabolism
  • Proto-Oncogene Proteins / antagonists & inhibitors*
  • Proto-Oncogene Proteins / chemistry*
  • Proto-Oncogene Proteins / metabolism
  • Substrate Specificity
  • Thiourea / chemistry*
  • Thiourea / metabolism
  • Thiourea / pharmacology*

Substances

  • Cell Cycle Proteins
  • Halogens
  • Protein Kinase Inhibitors
  • Proto-Oncogene Proteins
  • Protein Serine-Threonine Kinases
  • Thiourea